We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    mmy3007
Previous Study | Return to List | Next Study

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02195479
Recruitment Status : Active, not recruiting
First Posted : July 21, 2014
Last Update Posted : November 24, 2017
Sponsor:
Information provided by (Responsible Party):

July 18, 2014
July 21, 2014
November 24, 2017
December 9, 2014
July 16, 2021   (Final data collection date for primary outcome measure)
Progression-free Survival (PFS) [ Time Frame: Assess at approximately 41 months from randomization ]
The PFS is defined as time from date of randomization to either progressive disease (PD), or death, whichever occurs first. PD will be determined according to International Myeloma Working Group (IMWG) criteria.
Progression-free Survival (PFS) [ Time Frame: Assess at approximately 41 months from randomization ]
The PFS is duration from the date of randomization to date progressive disease will be documented or death due to any cause, whichever occurs first.
Complete list of historical versions of study NCT02195479 on ClinicalTrials.gov Archive Site
  • Time to Disease Progression (TTP) [ Time Frame: Assess at approximately 41 months from randomization ]
    The TTP is defined as the time from the date of randomization to the date of first documented evidence of PD as defined by IMWG criteria.
  • Complete Response (CR) [ Time Frame: Assess at approximately 41 months from randomization ]
    Percentage of participants with CR, as defined by the IMWG criteria.
  • Minimal Residual Disease (MRD) Negativity Rate [ Time Frame: Assess at approximately 41 months from randomization ]
    MRD negativity rate, defined as the proportion of participants who have negative MRD at any time point after the date of randomization.
  • Progression Free Survival on Next Line of Therapy (PFS2) [ Time Frame: Assess at approximately 41 months from randomization ]
    The PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death, whichever comes first. Disease progression will be based on Investigator judgment.
  • Time to Next Treatment [ Time Frame: Assess at approximately 41 months from randomization ]
    Time to next treatment is defined as the time from randomization to the start of the next-line treatment.
  • Overall Response Rate (ORR) [ Time Frame: Assess at approximately 41 months from randomization ]
    The ORR is defined as the proportion of participants who achieve PR or better according to IMWG criteria, during or after study treatment.
  • Stringent Complete Response (sCR) [ Time Frame: Assess at approximately 41 months from randomization ]
    The sCR rate is defined as the percentage of participants with sCR, as defined by the IMWG criteria.
  • Very Good Partial Response (VGPR) or Better [ Time Frame: Assess at approximately 41 months from randomization ]
    The VGPR or better rate, defined as the proportion of participants achieving VGPR and CR (including sCR) according to the IMWG criteria during or after the study treatment.
  • Time to Response [ Time Frame: Assess at approximately 41 months from randomization ]
    Time to response, defined as the time between randomization and the first efficacy evaluation that the participant has met all criteria for PR or better.
  • Duration of Response [ Time Frame: Assess at approximately 41 months from randomization ]
    Duration of response is time from the date of initial documentation of response (PR or better) to the date of first documented evidence of PD, as defined by IMWG criteria.
  • Overall Survival (OS) [ Time Frame: Assess at approximately 41 months after first participant randomized up to a maximum of 5 years after last participant is dosed ]
    The OS is defined as the time from the date of randomization to the date of the participant's death.
  • Impact of D-VMP compared to VMP on patient-reported perception of global health. [ Time Frame: Assess at approximately 41 months from randomization ]
    The EORTC-QLQ-C30, EQ-5D-5L is a generic measure of health status which is a 5 item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
  • Clinical efficacy of D-VMP in high risk molecular subgroups compared to VMP alone. [ Time Frame: Assess at approximately 41 months from randomization ]
    Clinical efficacy will be compared in high risk molecular subgroups between DVMP and VMP.
  • Time to Disease Progression (TTP) [ Time Frame: Assess at approximately 41 months from randomization ]
    The TTP is defined as the time from the date of randomization to the date of first documented evidence of PD.
  • Percentage of Participants Achieving Stringent Complete Response (sCR) [ Time Frame: Assess at approximately 41 months from randomization ]
    The sCR as defined by the IMWG criteria.
  • Percentage of Participants Achieving Complete Response (CR) [ Time Frame: Assess at approximately 41 months from randomization ]
    The CR as defined by the IMWG criteria.
  • Progression Free Survival on Next Line of Therapy (PFS2) [ Time Frame: Assess at approximately 41 months from randomization ]
    The PFS2 is defined as the time from randomization to disease progression on the next line of treatment or death, whichever comes first.
  • Percentage of Participants With Minimal Residual Disease (MRD) [ Time Frame: Week 58, 84, and 110 ]
    The MRD will be assessed in participants who achieve >= very good partial response (VGPR) by analyzing bone marrow aspiration specimens.
  • Time to Next Treatment [ Time Frame: Assess at approximately 41 months from randomization ]
    Time to next treatment is defined as the time from randomization to the start of the next-line treatment.
  • Overall Response Rate (ORR) [ Time Frame: Assess at approximately 41 months from randomization ]
    The ORR is defined as the percentage of participants who achieve CR or partial response (PR), according to the IMWG criteria, during or after the study treatment.
  • Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better [ Time Frame: Assess at approximately 41 months from randomization ]
    The VGPR will be defined by the IMWG criteria.
  • Duration of Response [ Time Frame: Assess at approximately 41 months from randomization ]
    Duration of response is calculated from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria.
  • Overall Survival (OS) [ Time Frame: Assess at approximately 41 months after first patient randomized up to a maximum of 5 years after last participant is dosed ]
    The OS is defined as duration between date of randomization to the date of the participant's death.
Not Provided
Not Provided
 
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy and autologous stem cell transplant (ASCT).
The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants will receive Velcade MelphalanPrednisone (VMP) alone and Treatment B: participants will receive daratumumab in combination with VMP).Two interim analyses are planned. The first will be to evaluate safety after a total of approximately 100 participants have been treated for at least 2 cycles or discontinued the study treatment. The second will be to evaluate cumulative interim safety and efficacy data, and will be performed when approximately 216 PFS events have been accumulated. The maximum duration of the study will be 5 years after the last participant is randomized or after 330 participants have died, whichever comes first. Efficacy will be primarily measured by comparison of PFS between the two treatment arms. Participants' safety will be monitored throughout the study.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: Velcade
    Participants will receive velcade 1.3 mg/m^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
  • Drug: Melphalan
    Participants will receive melphalan 9 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
  • Drug: Prednisone
    Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
  • Drug: Daratumumab
    Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end.
  • Drug: Dexamethasone
    Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab infusion as pre medication and prednisone substitute.
  • Active Comparator: Treatment Arm A (VMP Alone)
    Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
    Interventions:
    • Drug: Velcade
    • Drug: Melphalan
    • Drug: Prednisone
  • Experimental: Treatment Arm B (D-VMP)
    Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab infusion as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4.
    Interventions:
    • Drug: Velcade
    • Drug: Melphalan
    • Drug: Prednisone
    • Drug: Daratumumab
    • Drug: Dexamethasone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
706
October 20, 2021
July 16, 2021   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participant must have documented multiple myeloma satisfying the calcium elevation, renal insufficiency, anemia, and bone abnormalities (CRAB) diagnostic criteria, monoclonal plasma cells in the bone marrow greater than or equal to 10 percent (%) or presence of a biopsy proven plasmacytoma, and measurable secretory disease, as assessed by the central laboratory, and defined in protocol
  • Participants who are newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplantation (SCT) due to: being age >=65 years, or in participants <65 years: presence of important comorbid conditions likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation
  • Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
  • Meet the clinical laboratory criteria as specified in the protocol
  • A woman of childbearing potential must have a negative serum pregnancy test at screening within 14 days prior to randomization
  • Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin prior to dosing. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy

Exclusion Criteria:

  • Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma
  • Participant has a diagnosis of Waldenstrom's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of corticosteroids before treatment
  • Participant has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute common terminology criteria for adverse events (NCI CTCAE) Version 4
  • Participant has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years)
  • Participant has had radiation therapy within 14 days of randomization
  • Participant has had plasmapheresis within 28 days of randomization
  • Participant has known chronic obstructive pulmonary disease (COPD) (defined as a forced expiratory volume in 1 second [FEV1] <50% of predicted normal), known moderate or severe persistent asthma within the last 2 years or currently has uncontrolled asthma of any classification (controlled intermittent asthma or controlled mild persistent asthma is allowed)
  • Participants with known or suspected COPD must have a FEV1 test during screening
  • Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
  • Participant has any concurrent medical or psychiatric condition or disease (example active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Belgium,   Brazil,   Bulgaria,   Croatia,   Czechia,   Georgia,   Germany,   Greece,   Hungary,   Japan,   Korea, Republic of,   Macedonia, The Former Yugoslav Republic of,   Poland,   Portugal,   Romania,   Russian Federation,   Serbia,   Spain,   Turkey,   Ukraine,   United Kingdom,   United States
Czech Republic
 
NCT02195479
CR104761
54767414MMY3007 ( Other Identifier: Janssen Research and Development, LLC )
2014-002272-88 ( EudraCT Number )
Yes
Not Provided
Not Provided
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Not Provided
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Janssen Research & Development, LLC
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP